Tag: Transcytosis

Approximately 98% of all small-molecule drugs and nearly 100% of larger therapeutics are unable to cross the blood-brain barrier (BBB). Understanding **what drug can cross the blood-brain barrier** is critical for developing effective treatments for neurological diseases like Alzheimer's and Parkinson's.

Over 98% of small-molecule drugs are unable to cross the blood-brain barrier (BBB), presenting a major challenge for treating central nervous system (CNS) disorders. Understanding **which of these are ways substances can cross the blood-brain barrier?** is crucial for developing targeted therapies and navigating this protective physiological filter.

The blood-brain barrier (BBB) prevents entry of over 98% of small-molecule drugs and virtually all large-molecule therapeutics into the brain. Understanding what are the transport routes across the blood brain barrier is therefore critical for developing effective medications for central nervous system disorders.

Over 98% of small molecule drugs and virtually 100% of large molecule drugs cannot effectively cross the blood-brain barrier (BBB). This highly selective blockade necessitates a deeper understanding of what is the main mode of transport of drugs across the blood-brain barrier, which varies significantly depending on the drug's properties.